ethyl 1-methyl-2,3-dihydro-1H-indole-2-carboxylate | 97608-35-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 1-methyl-2,3-dihydro-1H-indole-2-carboxylate
• 英文别名: ethyl 1-methyl-1H-indole-2-carboxylate；ethyl 1-methyl-indoline-2-carboxylate；2,3-dihydro-2-ethoxycarbonyl-1-methyl-1H-indole；ethyl 1-methyl-2,3-dihydroindole-2-carboxylate
• CAS: 97608-35-0
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: FODKYKIENWVVKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  306.3±30.0 °C(Predicted)
• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 1-methyl-2,3-dihydro-1H-indole-2-carboxylate 在 palladium on activated charcoal 三氯化铝 、 氢气 、 三甲基铝 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 80.25h， 生成 2-(4,5-dihydro-1H-imidazol-2-yl)-2,3-dihydro-1-methyl-5-(phenylmethyl)-1H-indole
  参考文献：
  名称：

  .alpha.2-Adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines

  摘要：

  The synthesis and alpha 2-adrenergic activity of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines are described. The indolin-2-yl imidazoline 4b was found to possess potent alpha 2-adrenergic agonist and antagonist activity. The modification of the substituents on the indoline ring of 4b has led to the separation of these activities. Substitution on the aromatic ring of 4b with halogen or increasing the size of the N-alkyl substituent of 4b gave alpha 2-adrenergic antagonists without agonist activity. The N-allylindoline 4d is more potent than idazoxan in vitro and is equipotent in vivo, but is less receptor selective (alpha 2 vs. alpha 1) than idazoxan. The cis-1,3-dimethylindolin-2-yl imidazoline 6a is an alpha 2-adrenergic agonist equal in potency to clonidine in vitro, while the trans-1,3-dimethylindolin-2-yl imidazoline 6b is a moderately potent alpha 2-adrenergic antagonist.

  DOI：

  10.1021/jm00392a005
• 作为产物：
  描述：

  吲哚-2-羧酸乙酯 在 potassium sulfate 、 sodium cyanoborohydride 作用下， 以 三氟乙酸 为溶剂， 反应 2.0h， 生成 ethyl 1-methyl-2,3-dihydro-1H-indole-2-carboxylate
  参考文献：
  名称：

  Indoline analogs of idazoxan: potent .alpha.2-antagonists and .alpha.1-agonists

  摘要：

  The synthesis and alpha-adrenergic activity of a series of substituted 2-imidazolinylindolines are described. Substitution in the indoline ring generated compounds with a spectrum of adrenoceptor antagonist/agonist profiles that proved sensitive to both the nature and position of the substituent. Many of the derivatives possess greater presynaptic antagonist potency than the corresponding benzodioxan 1, dihydrobenzofuran 2, and indan 3 analogues; however, this alpha 2-antagonism is often accompanied by alpha 1-agonist activity. It was not possible to separate alpha 2-antagonist from alpha 1-agonist properties in this series. Compounds of most interest proved to be the N-ethyl 6, 5-chloro-N-methyl 18, and 5-chloro-N-ethyl 23 derivatives, all being potent alpha 2-antagonists and alpha 1-agonists. Substitution at the 4- and 7-position of the indoline ring generally gave compounds with nonselective agonist properties.

  DOI：

  10.1021/jm00400a009

文献信息

• Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles,
  申请人：Sterling Drug Inc.

  公开号：US05017584A1

  公开（公告）日：1991-05-21

  2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydro-1H-indoles, 2-(4,5-dihydro-1H-imidazol-2-yl)-1,2,3,4-tetrahydroquinolines and 2-(4,5-dihydro-1H-imidazol-2-yl)-1H-indoles, useful as antidepressant agents, are prepared by reacting a respective lower-alkyl 2,3-dihydro-1H-indole-2-carboxylate 1,2,3,4-tetrahydroquinoline-2-carboxylate or 1H-indole-2-carboxylate derivative with ethylenediamine or an N-lower-alkylethylenediamine in the presence of a Lewis-type acid.

  2-(4,5-二氢-1H-咪唑-2-基)-2,3-二氢-1H-吲哚，2-(4,5-二氢-1H-咪唑-2-基)-1,2,3,4-四氢喹啉和2-(4,5-二氢-1H-咪唑-2-基)-1H-吲哚，作为抗抑郁剂有用，通过将相应的低烷基2,3-二氢-1H-吲哚-2-羧酸酯，1,2,3,4-四氢喹啉-2-羧酸酯或1H-吲哚-2-羧酸酯衍生物与乙二胺或N-低烷基乙二胺在Lewis型酸存在下反应制备。
• SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS
  申请人：Purdue Pharma L.P.

  公开号：US20150057300A1

  公开（公告）日：2015-02-26

  The present disclosure provides substituted piperidines or pyrrolidines having Formula IA: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2a , R 2b , R 6 , A, X, m and n are defined as set forth in the specification. In certain embodiments, Compounds of the present disclosure are useful for treating pain. The present disclosure is also directed to the use of Compounds of the present disclosure to treat a disorder responsive to blockade of one or more sodium channels.

  本公开提供具有公式IA的取代哌啶或吡咯烷： 及其药用可接受的盐和溶剂化物，其中R1，R2a，R2b，R6，A，X，m和n按说明书定义。在某些实施方式中，本公开的化合物可用于治疗疼痛。本公开还涉及使用本公开的化合物来治疗对阻断一个或多个钠通道有反应的疾病。
• PYRIDINES AND PYRIMIDINES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20170008882A1

  公开（公告）日：2017-01-12

  The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W 1 , W 2 , W 3 , and R 5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.

  本公开提供了Formula I的吡啶和嘧啶以及其药用可接受的盐和溶剂化合物：其中A、G、W1、W2、W3和R5如规范中所述。本公开还提供了Formula I化合物及其药用可接受的盐和溶剂的用途。在某些实施例中，本公开的化合物对治疗疼痛有用。在另一实施例中，本公开的化合物对治疗对钠通道阻滞有反应的疾病，或缓解该疾病的症状有用。
• [EN] PYRIDINES AND PYRIMIDINES AND USE THEREOF<br/>[FR] PYRIDINES ET PYRIMIDINES, ET LEUR UTILISATION
  申请人：PURDUE PHARMA LP

  公开号：WO2015112801A1

  公开（公告）日：2015-07-30

  The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W1, W2, W3, and R5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.

  本公开提供了式I的吡啶和嘧啶以及其药用可接受的盐和溶剂化合物：其中A、G、W1、W2、W3和R5的定义如规范中所述。本公开还提供了式I化合物及其药用可接受的盐和溶剂的用途。在某些实施例中，本公开的化合物对治疗疼痛有用。在另一实施例中，本公开的化合物对治疗对钠通道阻滞有反应的疾病，或者缓解该疾病的症状有用。
• NOVEL COMPOUNDS
  申请人：Gottschling Dirk

  公开号：US20110195954A1

  公开（公告）日：2011-08-11

  The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R 1 , R 2 , R 3 and R 4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

  本发明涉及一般式I的新CGRP拮抗剂，其中U、V、X、Y、R1、R2、R3和R4如描述中所述定义，其互变异构体、异构体、顺反异构体、对映异构体、水合物、混合物及其盐，以及其盐的水合物，特别是与无机或有机酸或碱形成的生理上可接受的盐，包含这些化合物的药物、其用途以及其制备方法。